Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 67 articles:
HTML format
Text format



Single Articles


    July 2017
  1. JABBOUR E, Short NJ, Ravandi F, Huang X, et al
    A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
    Cancer. 2017 Jul 14. doi: 10.1002/cncr.30883.
    PubMed     Text format     Abstract available


    June 2017
  2. ARIFFIN H, Azanan MS, Abd Ghafar SS, Oh L, et al
    Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging.
    Cancer. 2017 Jun 27. doi: 10.1002/cncr.30857.
    PubMed     Text format     Abstract available


  3. ZEIDAN AM, Hu X, Long JB, Wang R, et al
    Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30814.
    PubMed     Text format     Abstract available


  4. KANAGAL-SHAMANNA R, Jain P, Takahashi K, Short NJ, et al
    TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
    Cancer. 2017 Jun 13. doi: 10.1002/cncr.30810.
    PubMed     Text format     Abstract available


  5. RADICH JP
    Chronic myeloid leukemia: Global impact from a local laboratory.
    Cancer. 2017 Jun 6. doi: 10.1002/cncr.30776.
    PubMed     Text format    


    May 2017
  6. ALEXANDER TB, Wang L, Inaba H, Triplett BM, et al
    Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
    Cancer. 2017 May 30. doi: 10.1002/cncr.30791.
    PubMed     Text format     Abstract available


  7. MILLOT F, Dupraz C, Guilhot J, Suttorp M, et al
    Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
    Cancer. 2017 May 12. doi: 10.1002/cncr.30767.
    PubMed     Text format     Abstract available


  8. PERRY AM, Brunner AM, Zou T, McGregor KL, et al
    Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
    Cancer. 2017 May 2. doi: 10.1002/cncr.30639.
    PubMed     Text format     Abstract available


  9. MAURO MJ
    Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes)!
    Cancer. 2017 May 2. doi: 10.1002/cncr.30638.
    PubMed     Text format    


    April 2017
  10. CHEUNG YT, Brinkman TM, Mulrooney DA, Mzayek Y, et al
    Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in long-term survivors of childhood acute lymphoblastic leukemia.
    Cancer. 2017 Apr 27. doi: 10.1002/cncr.30742.
    PubMed     Text format     Abstract available


  11. SEGAL E, Martens M, Wang HL, Brazauskas R, et al
    Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
    Cancer. 2017 Apr 27. doi: 10.1002/cncr.30737.
    PubMed     Text format     Abstract available


  12. KHOURY HJ, Collins RH Jr, Blum W, Stiff PS, et al
    Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
    Cancer. 2017 Apr 14. doi: 10.1002/cncr.30696.
    PubMed     Text format     Abstract available


  13. BATTIPAGLIA G, Ruggeri A, Massoud R, El Cheikh J, et al
    Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30680.
    PubMed     Text format     Abstract available


  14. BODDU PC, Kantarjian HM, Ravandi F, Garcia-Manero G, et al
    Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30704.
    PubMed     Text format     Abstract available


    March 2017
  15. NAGLER A, Labopin M, Beelen D, Ciceri F, et al
    Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Cancer. 2017 Mar 22. doi: 10.1002/cncr.30646.
    PubMed     Text format     Abstract available


  16. RYTTING ME, Jabbour EJ, O'Brien SM, Kantarjian HM, et al
    Acute lymphoblastic leukemia in adolescents and young adults.
    Cancer. 2017 Mar 22. doi: 10.1002/cncr.30624.
    PubMed     Text format     Abstract available


    February 2017
  17. KONG JH, Winton EF, Heffner LT, Chen Z, et al
    Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Cancer. 2017 Feb 27. doi: 10.1002/cncr.30608.
    PubMed     Text format     Abstract available


  18. QU X, Othus M, Davison J, Wu Y, et al
    Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.
    Cancer. 2017 Feb 21. doi: 10.1002/cncr.30626.
    PubMed     Text format     Abstract available


  19. PAVLU J, Labopin M, Zoellner AK, Sakellari I, et al
    Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT.
    Cancer. 2017 Feb 17. doi: 10.1002/cncr.30604.
    PubMed     Text format     Abstract available


  20. LAUSEKER M, Hasford J, Saussele S, Kremers S, et al
    Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.
    Cancer. 2017 Feb 13. doi: 10.1002/cncr.30636.
    PubMed     Text format     Abstract available


  21. JAIN P, Thompson PA, Keating M, Estrov Z, et al
    Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30596.
    PubMed     Text format     Abstract available


    January 2017
  22. MICHELIS FV, Gupta V, Zhang MJ, Wang HL, et al
    Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Cancer. 2017 Jan 24. doi: 10.1002/cncr.30567.
    PubMed     Text format     Abstract available


  23. WEISDORF DJ, Millard HR, Horowitz MM, Hyare PS, et al
    Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.
    Cancer. 2017 Jan 24. doi: 10.1002/cncr.30536.
    PubMed     Text format     Abstract available


  24. NABBOUH AI, Hleihel RS, Saliba JL, Karam MM, et al
    Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Cancer. 2017 Jan 5. doi: 10.1002/cncr.30515.
    PubMed     Text format     Abstract available


    December 2016
  25. ROUSSELOT P, Prost S, Guilhot J, Roy L, et al
    Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30490.
    PubMed     Text format     Abstract available


  26. GORIN NC, Labopin M, Czerw T, Pabst T, et al
    Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the Eu
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30400.
    PubMed     Text format     Abstract available


    November 2016
  27. WAGNER B, da Silva Nardi F, Schramm S, Kraemer T, et al
    HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia.
    Cancer. 2016 Nov 2. doi: 10.1002/cncr.30427.
    PubMed     Text format     Abstract available


    October 2016
  28. KOLLER PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, et al
    Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
    Cancer. 2016 Oct 20. doi: 10.1002/cncr.30362.
    PubMed     Text format     Abstract available


  29. ISSA GC, Kantarjian HM, Yin CC, Qiao W, et al
    Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
    Cancer. 2016 Oct 3. doi: 10.1002/cncr.30376.
    PubMed     Text format     Abstract available


    September 2016
  30. ANTILLON FG, Blanco JG, Valverde PD, Castellanos M, et al
    The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results.
    Cancer. 2016 Sep 28. doi: 10.1002/cncr.30257.
    PubMed     Text format     Abstract available


  31. RAVANDI F, Jorgensen J, Borthakur G, Jabbour E, et al
    Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
    Cancer. 2016 Sep 22. doi: 10.1002/cncr.30361.
    PubMed     Text format     Abstract available


  32. MUFFLY L, Lichtensztajn D, Shiraz P, Abrahao R, et al
    Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.
    Cancer. 2016 Sep 13. doi: 10.1002/cncr.30322.
    PubMed     Text format     Abstract available


  33. RAO P, Li Y, Getz KD, Miller TP, et al
    Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals.
    Cancer. 2016 Sep 12. doi: 10.1002/cncr.30225.
    PubMed     Text format     Abstract available


  34. JABBOUR E, Short NJ, Jorgensen JL, Yilmaz M, et al
    Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Cancer. 2016 Sep 7. doi: 10.1002/cncr.30264.
    PubMed     Text format     Abstract available


    August 2016
  35. ARCHER NP, Perez-Andreu V, Scheurer ME, Rabin KR, et al
    Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics.
    Cancer. 2016 Aug 16. doi: 10.1002/cncr.30241.
    PubMed     Text format     Abstract available


  36. CREUTZIG U, Zimmermann M, Reinhardt D, Rasche M, et al
    Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.
    Cancer. 2016 Aug 16. doi: 10.1002/cncr.30220.
    PubMed     Text format     Abstract available


  37. TAKAHASHI K, Kantarjian HM, Yang Y, Sasaki K, et al
    A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.
    Cancer. 2016 Aug 10. doi: 10.1002/cncr.30197.
    PubMed     Text format     Abstract available


  38. SHORT NJ, Kantarjian HM, Sasaki K, Cortes JE, et al
    Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Cancer. 2016 Aug 10. doi: 10.1002/cncr.30262.
    PubMed     Text format     Abstract available


  39. SASAKI K, Jabbour EJ, Ravandi F, Short NJ, et al
    Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
    Cancer. 2016 Aug 1. doi: 10.1002/cncr.30231.
    PubMed     Text format     Abstract available


    July 2016
  40. KADIA TM, Jain P, Ravandi F, Garcia-Manero G, et al
    TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.
    Cancer. 2016 Jul 26. doi: 10.1002/cncr.30203.
    PubMed     Text format     Abstract available


    June 2016
  41. FREEMAN AT, Meyer AM, Smitherman AB, Zhou L, et al
    Statewide geographic variation in outcomes for adults with acute myeloid leukemia in North Carolina.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30139.
    PubMed     Text format     Abstract available


  42. GIDDINGS BM, Whitehead TP, Metayer C, Miller MD, et al
    Childhood leukemia incidence in California: High and rising in the Hispanic population.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30129.
    PubMed     Text format     Abstract available


  43. DEOL A, Sengsayadeth S, Ahn KW, Wang HL, et al
    Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30140.
    PubMed     Text format     Abstract available


  44. GIEBEL S, Czyz A, Ottmann O, Baron F, et al
    Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the acute leukemia working party of
    Cancer. 2016 Jun 16. doi: 10.1002/cncr.30130.
    PubMed     Text format     Abstract available


  45. BORTHAKUR G, Popplewell L, Boyiadzis M, Foran J, et al
    Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
    Cancer. 2016;122:1871-9.
    PubMed     Text format     Abstract available


  46. KAHN JM, Keegan TH, Tao L, Abrahao R, et al
    Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma.
    Cancer. 2016 Jun 10. doi: 10.1002/cncr.30089.
    PubMed     Text format     Abstract available


    May 2016
  47. THOMPSON PA, Stingo F, Keating MJ, Ferrajoli A, et al
    Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
    Cancer. 2016 May 16. doi: 10.1002/cncr.30069.
    PubMed     Text format     Abstract available


  48. FATHI AT, DeAngelo DJ, Stevenson KE, Kolitz JE, et al
    Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.
    Cancer. 2016 May 12. doi: 10.1002/cncr.30037.
    PubMed     Text format     Abstract available


  49. HAAVISTO A, Henriksson M, Heikkinen R, Puukko-Viertomies LR, et al
    Sexual function in male long-term survivors of childhood acute lymphoblastic leukemia.
    Cancer. 2016 May 12. doi: 10.1002/cncr.29989.
    PubMed     Text format     Abstract available


  50. KANTARJIAN HM, Stein AS, Bargou RC, Grande Garcia C, et al
    Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from two phase 2 studies.
    Cancer. 2016 May 3. doi: 10.1002/cncr.30031.
    PubMed     Text format     Abstract available


  51. GALLOWAY-PENA JR, Smith DP, Sahasrabhojane P, Ajami NJ, et al
    The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia.
    Cancer. 2016 May 3. doi: 10.1002/cncr.30039.
    PubMed     Text format     Abstract available


    April 2016
  52. AZUERO A
    A note on the magnitude of hazard ratios.
    Cancer. 2016;122:1298-9.
    PubMed     Text format    


  53. BORATE UM, Mineishi S, Costa LJ
    Reply to a note on the magnitude of hazard ratios.
    Cancer. 2016;122:1299-300.
    PubMed     Text format    


    March 2016
  54. KUNIN-BATSON AS, Lu X, Balsamo L, Graber K, et al
    Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study.
    Cancer. 2016 Mar 29. doi: 10.1002/cncr.29946.
    PubMed     Text format     Abstract available


  55. CZERW T, Labopin M, Gorin NC, Giebel S, et al
    Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the acute leukemia working party of the European Society for Blood and
    Cancer. 2016 Mar 28. doi: 10.1002/cncr.29990.
    PubMed     Text format     Abstract available


  56. SCHIFFER CA, Cortes JE, Hochhaus A, Saglio G, et al
    Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Cancer. 2016 Mar 21. doi: 10.1002/cncr.29933.
    PubMed     Text format     Abstract available


  57. BOSE P, Verstovsek S
    The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
    Cancer. 2016;122:681-92.
    PubMed     Text format     Abstract available


    February 2016
  58. TRICOLI JV, Blair DG, Anders CK, Bleyer A, et al
    Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.
    Cancer. 2016 Feb 5. doi: 10.1002/cncr.29871.
    PubMed     Text format     Abstract available


    January 2016
  59. DUPUIS LL, Lu X, Mitchell HR, Sung L, et al
    Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group.
    Cancer. 2016 Jan 15. doi: 10.1002/cncr.29876.
    PubMed     Text format     Abstract available


  60. LIPSHULTZ SE, Anderson LM, Miller TL, Gerschenson M, et al
    Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
    Cancer. 2016 Jan 13. doi: 10.1002/cncr.29872.
    PubMed     Text format     Abstract available


    December 2015
  61. FALCHI L, Verstovsek S, Ravandi-Kashani F, Kantarjian HM, et al
    The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.
    Cancer. 2015 Dec 30. doi: 10.1002/cncr.29852.
    PubMed     Text format     Abstract available


  62. HAKIM H, Dallas R, Zhou Y, Pei D, et al
    Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia.
    Cancer. 2015 Dec 23. doi: 10.1002/cncr.29833.
    PubMed     Text format     Abstract available



  63. Recurrence, poor survival more likely in patients with acute myeloid leukemia who have certain mutations.
    Cancer. 2015;121:4275.
    PubMed     Text format    


  64. EL-JAWAHRI AR, Vandusen HB, Traeger LN, Fishbein JN, et al
    Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation.
    Cancer. 2015 Dec 9. doi: 10.1002/cncr.29818.
    PubMed     Text format     Abstract available


  65. CHURPEK JE, Marquez R, Neistadt B, Claussen K, et al
    Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
    Cancer. 2015 Dec 7. doi: 10.1002/cncr.29615.
    PubMed     Text format     Abstract available


  66. KARP JE, Wolff AC
    Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.
    Cancer. 2015 Dec 7. doi: 10.1002/cncr.29613.
    PubMed     Text format    


    November 2015
  67. THOMPSON PA, O'Brien SM, Xiao L, Wang X, et al
    beta -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
    Cancer. 2015 Nov 20. doi: 10.1002/cncr.29794.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: